|
Generic Maker’s Appeals Court Loss Highlights Preemption Loophole
A federal appeals court has poked a hole in generic-drug makers’ preemption protection, ruling that companies should simply stop producing a drug if it is unsafe and the warning label doesn’t reflect all concerns.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives